65685-49-6

Upstream product

• 61799-77-7 2,N-dihydroxy-5-methylbenzamide 
• 22717-57-3 methyl 6-hydroxy-m-toluate 
• 61799-77-7 2,N-dihydroxy-5-methyl-benzamide 

Downstream Products

• 1299489-82-9 5-bromomethyl-3-(tetrahydro-pyran-2-yloxy)-benzo[d]isoxazole 
• 1299489-59-0 5-methyl-2-trityl-benzoisoxazol-3-one 
• 1299489-77-2 5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-ol 
• 1299489-85-2 [5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-yloxy]-acetic acid 
• 1299489-93-2 3-[5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-yloxy]-propionic acid 
• 1299490-58-6 5-(2',4',5'-trifluoro-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-ol 
• 1299489-57-8 5-bromomethyl-2-trityl-benzo[d]isoxazol-3-one 
• 1299489-83-0 5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-3-(tetrahydro-pyran-2-yloxy)benzo[d]isoxazole 
• 1299489-95-4 3-[5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-yloxy]-propionic acid tert-butyl ester 
• 1299490-59-7 5-(2',4',5'-trifluoro-biphenyl-4-yloxymethyl)-2-trityl-benzo[d]isoxazol-3-one 
• 1299489-86-3 [5-(4',5'-difluoro-2'-methoxy-biphenyl-4-yloxymethyl)-benzo[d]isoxazol-3-yloxy]-acetic acid ethyl ester 
• 196708-35-7 3-chloro-5-methyl-1,2-benzisoxazole 

Relevant academic research and scientific papers

BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful

Benzo[d]isoxazol-3-ol DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein Z1 is N or CR3; Z2 is N or CR4; Z3is O or S; A is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R1, R2, R3 and R4 is other than hydrogen; and at least one of Z1 and Z2 is other than N.

BENZISOXAZOLES

The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer from 1 to 3; X represents amino, hydroxy, -oxo or -Z-R1; Y is absent when X represents -Z-R1 and -(C=O)-R66 when X represents oxo; Z represents carbonyl, -oxy-carbonyl- or -NR 55-carbonyl-; R1 represents C1-4alkyl, Ar1, Ar1-C1-4a1ky1-, -NR3R4 or -Het1; R2 represents hydrogen, halo, nitro, hydroxycarbonyl-, C1-4alkyloxy or C1-4alkyl; R33 and R4 are each independently selected from hydrogen, Ar33 or C1-4alkyl; R5 represents hydrogen, C1-4alkylcarbonyl- or Ar4-carbonyl-; R6 represents a substituent selected from the group consisting of C1.4alkyl, Ar55, Ar6-C1-4alkyl- or NR7R8; R7 and R8 are each independently selected from hydrogen, Het4 or C1-4alkyl; Het1 represents a heterocycle selected from oxazolyl, isoxazolyl, imidazolyl or pyrazolyl wherein said heterocycle is optionally substituted with one, two or three substituents selected from the group consisting of amino, C1-4alkyl, hydroxy-C1-4alkyl, phenyl, phenyl-C1-4alkyl- and phenyl substituted with one or more halo substituents; Het4 represents a heterocycle selected from oxazolyl or isoxazolyl, wherein said heterocycle is optionally substituted with one or more substituents selected from the group consisting of amino, C1-4alkyl, hydroxy-C1-4alkyl-, phenyl, phenyl-Cl-4alkyl and phenyl substituted with one or more halo substituents; and Ar1, Ar2, Ar3, Ar4, Ar5 or Ar6 each independently represents phenyl optionally substituted one or where possible two or more substituents selected from halo, nitro, C1-4alkyl, hydroxy or C1-4alkyloxy-.

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

Isoxazole derivatives

An isoxazole compound having the following formula: wherein R1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.